Brain tumour
Article
|Published
The purpose of the population survey is to map how disease and treatment affect function and quality of life for people with brain tumors.
Population survey on brain tumours (benign or malignant)
Individuals who have been treated for a benign or malignant brain tumour are now being given the opportunity to report on their health and quality of life approximately one year after treatment, and again one and four years later.
Living with late effects after treatment for a brain tumour can be challenging, and it is important for this patient group that we obtain an overview of the burden and duration of such late effects, as well as how they impact quality of life. Through this population survey, the health and quality of life of people who have been treated for a brain tumour, as well as individuals who have never been diagnosed with a brain tumour, will be assessed. This will allow us to gain insight into how common various late effects are and who is affected, for example depending on the type of treatment they receive.
Because individuals without any history of brain tumours are also invited, we will be able to better understand which symptoms are more common in the general population and may be related to, for example, aging, and which symptoms can be attributed to the diagnosis and treatment.
We use translations of validated questionnaires from the European Organisation for Research and Treatment of Cancer (EORTC) in the survey. Individuals who have been treated for a benign or malignant brain tumour from 1 January 2025 onwards will receive an invitation to participate.